Furthermore, we also explored the impact of mutant TET2 on OS in AML patients under 65 years of age, figuring out a pooled HRs of 1.310 (95%CI: 0.999–1.718; P = 0.051; heterogeneity: I2 = 24.6%, P = 0.264; Fig. 2c), while the pooled HRs for EFS in the same cohort were 1.724 (95%CI: 1.007–2.954; P = 0.047; heterogeneity: I2 = 56.1%, P = 0.077) and became 1.429 (95%CI: 1.041–1.962, P = 0.027; heterogeneity: I2 = 37.4%, P = 0.202) after the study of Cher and colleagues was excluded (Additional file 1: Figure S1c-1d). This evidence concerns the gene TET2 and acute myeloid leukemia.